Investors

2018 Press Releases

Keyword Search
2018 | 2017 | 2016 | 2015
DateTitle Download Print
10/04/18BrainStorm Poster Receives Clinical Abstract Award at NEALS ConferenceDownload PDFPrinter Friendly Version
10/03/18BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALSDownload PDFPrinter Friendly Version
09/13/18BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn®Download PDFPrinter Friendly Version
09/12/18BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy PlatformDownload PDFPrinter Friendly Version
09/05/18BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor ConferenceDownload PDFPrinter Friendly Version
09/04/18BrainStorm Appoints Arturo Araya as Chief Commercial OfficerDownload PDFPrinter Friendly Version
08/29/18BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor ConferenceDownload PDFPrinter Friendly Version
08/23/18BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALSDownload PDFPrinter Friendly Version
07/25/18BrainStorm Announces Grant of a New European Patent for NurOwn®Download PDFPrinter Friendly Version
07/23/18BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate UpdateDownload PDFPrinter Friendly Version
07/17/18BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23Download PDFPrinter Friendly Version
07/05/18BrainStorm Granted Japanese Patent for NurOwn®Download PDFPrinter Friendly Version
07/02/18BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® ProductionDownload PDFPrinter Friendly Version
06/28/18BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph PetrozielloDownload PDFPrinter Friendly Version
06/26/18BrainStorm Provides Update on "Right to Try" PolicyDownload PDFPrinter Friendly Version
06/25/18BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" PolicyDownload PDFPrinter Friendly Version
06/07/18BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 ShareDownload PDFPrinter Friendly Version
06/01/18BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill SigningDownload PDFPrinter Friendly Version
05/30/18BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International ConventionDownload PDFPrinter Friendly Version
05/25/18BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation Printer Friendly Version
05/14/18BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical HighlightsDownload PDFPrinter Friendly Version
05/09/18BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in LondonDownload PDFPrinter Friendly Version
05/08/18Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14Download PDFPrinter Friendly Version
05/01/18BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering ConferenceDownload PDFPrinter Friendly Version
04/11/18BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New YorkDownload PDFPrinter Friendly Version
04/09/18Letter To ShareholdersDownload PDFPrinter Friendly Version
03/28/18BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian PatientsDownload PDFPrinter Friendly Version
03/21/18BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory BoardDownload PDFPrinter Friendly Version
03/15/18BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor ForumDownload PDFPrinter Friendly Version
03/12/18BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to ChairDownload PDFPrinter Friendly Version
03/08/18BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017Download PDFPrinter Friendly Version
03/05/18BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8Download PDFPrinter Friendly Version
02/07/18BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, CaliforniaDownload PDFPrinter Friendly Version
02/06/18BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor ConferenceDownload PDFPrinter Friendly Version
02/05/18BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of DirectorsDownload PDFPrinter Friendly Version
01/16/18BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22Download PDFPrinter Friendly Version
01/03/18BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®Download PDFPrinter Friendly Version